Latest News
-
Trump is ready to launch a second phase of sanctions against Russia over the Ukraine conflict
Donald Trump, U.S. president, said Sunday that he was ready to move into a second phase in sanctioning Russia. This is the closest he's come to implying he might be about to ramp up sanctions against Moscow and its oil purchasers over the war with Ukraine. Trump has repeatedly warned Moscow of further sanctions, but he withheld them while pursuing peace talks. Trump did not commit to a decision, nor did he specify what the second phase would entail. When asked by a White House reporter if he was ready to move on to the "second phase" of sanctions, Trump replied, "Yeah. I am." He didn't elaborate. Trump is frustrated at his inability, after taking office in January, to quickly end the conflict in Ukraine. The White House didn't immediately respond to a Sunday email seeking comments about the steps Trump is considering. The exchange followed Trump's Wednesday comments defending his actions against Russia, which included imposing punitive duties on India's exports to the U.S. last month. India is the largest buyer of Russia’s energy exports. Western buyers, however, have reduced their purchases in response to war. Trump stated on Wednesday that "that cost Russia hundreds of billions" of dollars. "You call this no action?" "You call that no action?" Treasury Secretary Scott Bessent stated on Sunday that both the U.S. & the European Union can impose "secondary tariffs" on countries who buy Russian oil, pushing the Russian economy into a state of crisis and forcing Russian President Vladimir Putin at the negotiation table. China is the largest buyer of Russian energy.
-
OPEC+ agrees to increase oil production from October in order to gain market share
OPEC+ agreed to increase oil production in October, as Saudi Arabia tries to regain its market share. However, the pace will be slower than previous months because of an expected weakening of demand worldwide. OPEC+ increased production in April, after years of cutting to support the oil markets. But the decision on Sunday to boost output further came as a shock amid a possible looming oil surplus during the winter months in the Northern Hemisphere. In a Sunday online meeting, eight members of OPEC+ decided to increase production by 137,000 barrels a day from October, according to OPEC+. This is a much smaller increase than the monthly increases that were about 555,000 bpd between September and August, and 411,000 bpd between July and June. Eight members of OPEC+ have begun unwinding a second tranche, which amounts to about 1,65 million bpd. This is more than a calendar year ahead of schedule. The group has already unwound its first tranche of 2,5 million bpd, which is equivalent to 2.4 percent of the global demand. The barrels are small but they send a powerful message, said Jorge Leon, an analyst at Rystad who is a former OPEC representative. The increase in barrels is not about volume but more about signalling – OPEC+ wants to gain market share, even if that means softer prices. Leon says that OPEC+ (made up of the Organization of the Petroleum Exporting Countries, Russia, and other allies) found it easy when the demand grew in the summer. But the real test comes in the fourth quarter, with the expected slowing of demand. OPEC+ stated that it had the option to increase, pause, or reverse increases at future meetings. The next meeting between the eight countries is scheduled for October 5. NEW CAPACITY Saudi Arabia's efforts to punish overproducing members like Kazakhstan and the United Arab Emirates for building new capacity have also contributed to the increase in OPEC output this year. In an effort to fulfill his promise made during the election to lower domestic gasoline prices, Donald Trump pressured the group earlier this year to increase production. As a result of the increased production, oil prices have fallen by around 15% this year. This has pushed oil company profits to their lowest level since the pandemic. The oil price has not fallen, but is still trading around $65 per barrel. This is due to the sanctions imposed by the West on Russia and Iran. This has encouraged OPEC+ producers to increase their output. OPEC+ has not met its pledged increases because the majority of members are operating at near-capacity. Analysts and data show that only Saudi Arabia and United Arab Emirates can add more barrels to the market. OPEC+ already had two levels of cuts in place before the Sunday agreement - the 1,65 million bpd reduction by the eight member countries, and a second 2 million bpd reduction by the entire group until 2026. (Additional reporting from Olesya Astakhova and Maha el Dhan; editing by Nick Zieminski, David Holmes and David Holmes).
-
Stellantis CEO asks EU to support the car sector
In order to protect the automotive industry, the new CEO of Stellantis, a carmaker in Greece, has called on the European Union (EU) to be flexible when it comes to the transition to electric cars. "A strategic dialog is important, but it's now vital to act urgently." Antonio Filosa became CEO of Stellantis in June. On September 12, European Commission President Ursula von der Leyen will host executives from the automotive industry to discuss the future. The sector is under threat due to the Chinese competition with electric vehicles, and U.S. Tariffs. Filosa is the head of Fiat, Alfa Romeo and Peugeot brands. Chrysler, Jeep and Opel are also part of the group. Filosa has called on the European Commission (EC) to encourage the sale of hybrid cars to reduce the average age of the vehicles on the roads. In a joint interview, he told Italy's Il Sole 24 Ore as well as France's Les Echos that a European policy encouraging the replacement of older vehicles with new ones and a wider range of powertrains could have a greater effect on global CO2 emission than an annual new car market. Filosa stated that the Light Commercial Vehicles sector is facing an urgent situation and suggested that the CO2 emission period for this category should be increased to five years, from three. As he reviewed the brand portfolio, he also tried to dispel speculation that Stellantis might seek a buyer of Maserati. He said: "I would like to be clear that Maserati was not for sale. We need to know which products we should develop and what long-term strategies to adopt for our iconic brand."
-
Daniel Craig reprises his role as Benoit Blanc, the detective in "Wake Up Dead Man: a Knives Out Mystery"
In "Wake Up Dead Man, A Knives Out Mystery", the third installment of the franchise, Daniel Craig's charismatic and sharply dressed Benoit Blanc is back to solve yet another murder case. It's dark, big and fun. The latest installment of the Whodunit genre from writer-director Rian Johnston takes place in a small town church in Upstate New York, with a more grounded tone. Johnson said on the red carpet before the Toronto International Film Festival premiere that they were trying to "do something different every time". "The first was a cozy mystery. The second was a broad, kind of vacation comedy mystery. "This one has a darker tone and is more gothic, but it's still fun," said he. Craig couldn't be more in agreement. "It is a departure. It's an entirely different movie. "But it's still Benoit blanc mystery", the former James Bond actor said. The ensemble cast includes Josh O'Connor (left), Glenn Close (right), Josh Brolin (center), Mila Kunis (right), Jeremy Renner and Kerry Washington. Also included are Andrew Scott, Cailee Spaeny, Daryl McCormack, Thomas Haden Church, and Andrew Scott. O'Connor was awash with praise for Johnson who he called his "idol". He said that Johnson was a "genius writer and director". The young British actor who played Prince Charles on the TV show "The Crown" received the most applause for his performance of a young priest following the premiere. Spaeny said that she was grateful to have the chance to play a cellist and enjoyed every moment on the set. The American actress, who learned the cello in preparation for her part, stars in her first comedy. She said, "It felt like we weren't being paid for this work." Craig also praised the cast for their "bubbly" nature. He said, "We have been extremely lucky in the entire series. We nailed it once again." The film will be released in limited theaters on November 26, before being streamed on Netflix starting December 12. (Reporting from Bhargav Asharya in Toronto, Editing by Caroline Stauffer & William Mallard
-
China's central banks buys gold for the 10th consecutive month in August
China's central banks added gold to their reserves in August, continuing purchases for a 10th consecutive month, according to official data released on Sunday. Gold, traditionally viewed as a safe asset in times of uncertainty, is up 35% on the year. It reached a record-high last week amid strong demand for investments and purchases from central banks, including those in China. China's gold reserves increased to 74.02 millions fine troy-ounces by the end August from 73.96 at the end July. According to the data released by the Central Bank, they were valued at 253.84 billion dollars, an increase from $243.99 at the end the previous month. The People's Bank of China, which is the head of research for online marketplace BullionVault, said that while China's gold purchasing has slowed down in 2025, it has increased its bullion reserve at prices ever higher. Beijing's continued accumulation of gold is a signal that it has faith in the metal as a reserve for long-term. This also boosts the confidence of China's investors and private households in gold. The demand for gold was low in the world's biggest producer and consumer this week due to the high price. Dealers offered discounts above the global benchmark, to lure buyers. (Reporting from Amy Lv and Polina Devitt in London for the Beijing Newsroom. Editing by Clarence Fernandez.)
-
After a four-day search, a Canadian soldier is found dead in Latvia
The Canadian military announced on Saturday that a member of the Canadian Armed Forces who was reported missing earlier this week in Latvia has been found deceased. The body of Warrant Officer George Hohl was discovered on Friday, after he disappeared on Tuesday, in the Baltic country where Canada has troops stationed as part a multinational brigade. Hohl worked as a Vehicle Technologist for the 408 Tactical Helicopter Squadron, based in Edmonton (Alberta). He was serving with the Aviation Battalion of NATO's Multinational Brigade - Latvia when he disappeared near the Adazi base. The Canadian Forces Military Police is assisting Latvian authorities to investigate the circumstances surrounding Hohl’s death. Officials have stated that "there are no indications this incident poses a greater threat to the safety and security of our deployed members." Jennie Carignan, Chief of Defence Staff and General Jennie Carignan, said that the loss was devastating to the entire Canadian Armed Forces. She added that Hohl will be remembered for his dedication. The warrant officer has served in multiple deployments, including disaster relief operations at home and tours with Operation REASSURANCE (Canada's contribution to NATO’s enhanced forward presence established after Russia's 2014 annexation Crimea). Operation REASSURANCE is a rotation of approximately 2,200 Canadians in the Baltic State. According to a statement from the Canadian military, an investigation is underway into Hohl’s death. (Reporting and editing by Nick Zieminski in Washington)
-
Ukraine drones hit training centre at Zaporizhzhia nuclear plant, Russian management says
The Russian-installed management of the Russia-held nuclear plant in Ukraine announced on Saturday that Ukrainian drones had hit the roof at the Zaporizhzhia training centre. There was no damage to the building and there was no radiation increase. In a Telegram message, the administration stated that the strike took place about 300 meters (984 feet) away from a nuclear reactor. The statement stated that "This centre is unique - it houses the only full scale simulator of a nuclear reactor hall in the world, which is crucial for staff training." Although the station is Europe's largest nuclear power plant, with six reactors and no power, it still needs power to keep nuclear fuel cool. Administration officials said that the attack did not disrupt the operation of the plant. The administration stated that "operational safety limits have not been violated, and radiation levels are normal." Ukraine has not yet responded. We could not independently confirm the Russian report. In the early weeks of Russia’s invasion of Ukraine in February 2022, Russian forces captured the Zaporizhzhia nuclear plant. Both sides accuse the other of triggering a nuclear disaster by firing weapons or other actions. Reporting by Lidia Kelley in Melbourne
-
Sources say that OPEC+ is likely to agree on a further increase in oil production on Sunday.
OPEC+ sources stated on Saturday that eight OPEC+ nations will likely increase oil production on Sunday, but they may add less oil in October than recent months due to the slowdown of global demand with the end driving season. OPEC+ reversed its April strategy of production cuts and has already increased quotas to about 2,4 million barrels a day (about 2.4% of the world's demand) to increase market share. This is in response to pressure from U.S. president Donald Trump, who wants to lower oil prices. These increases, however, have not had a significant impact on oil prices. They are currently trading at $66 per barrel, supported by Western sanctions against Russia and Iran. This encourages rivals like the United States to increase production. OPEC+ would start to unravel a second layer, averaging about 1.65 millions bpd. This would be more than a full year ahead of schedule. Two sources told me on Saturday that the focus of talks is to gradually unwind this entire cut, in monthly increments. On Sunday, 1230 GMT eight OPEC+ member countries will hold a virtual meeting. The focus of the discussion is likely to be October's output. An OPEC+ official said that the countries could increase their output by 135,000 bpd in October. Another said it might be closer to 200,000-350,000 bpd. The eight members increased production for September by 547,000 bpd at their last August meeting, giving a total of 2.5 million bpd increase for the entire year. This included an additional 300,000 bpd production allocation for the UAE. OPEC's headquarters and Saudi Arabian authorities did not respond to Wednesday's requests for comments. OPEC+ is the Organization of Petroleum Exporting Countries plus Russia, and other allies. Brent crude futures closed at $65.50 a bar on Friday, down by 2.2%. This was due to a disappointing U.S. employment report and the expectation of a production increase from OPEC+. It is still up since a low in 2025 of around $58 per barrel in April. Analysts have stated that sanctions and the fact that OPEC+ has not met its pledged amount have supported prices. OPEC+ has been reducing production to support the oil price for several years. The group has committed to a further 2 million bpd in cuts until 2026. (Reporting and editing by Alexandra Hudson, Olesya Almakhova, Alex Lawler Ahmad Ghaddar, Dmitry Zhdannikov)
Weight loss drug manufacturers are lining up to take advantage of a lucrative market, as the competition heats up
Novo Nordisk, Eli Lilly, and other pharmaceutical companies are in competition for the next generation of treatments for obesity.
In recent quarters, Eli Lilly’s Zepbound gained market share against Novo’s Wegovy -- a trend that led, in part to the Friday ouster of Novo CEO Lars Fruergaard Jorgensen.
Here is a list with weight loss drugs that are being developed by Novo, Lilly, and other companies in search of the next big treatment.
NOVO NORDISK
The Danish pharmaceutical company is developing several experimental weight loss drugs. These include a pill, a new-generation injection, called amycretin and a drug called CagriSema.
In an early stage trial last year, Novo's Amycretin, taken daily, led to a 13.1% weight reduction after only 12 weeks.
Early-mid-stage trials found that the shot version of amycretin caused patients to lose 22% of weight within 36 weeks.
CagriSema - touted as the potent successor of Wegovy - showed less-than-expected results in two late-stage studies. In one trial, the drug helped overweight patients reduce their weight by 22,7%. This was below Novo's expectation of 25%.
Novo intends to submit CagriSema to regulatory approval during the first quarter 2026.
Novo also has licensing agreements for drugs that are still in the testing stage, such as the $2 billion deal it signed with China's United Laboratories to develop a drug for weight loss called "triple G" which targets three hormones.
ELI LILLY
In a late-stage study, Lilly's weight-loss drug orforglipron has helped type 2 diabetics lose nearly 8% their body weight in 40 weeks.
This compares well with Novo's injectable drug Ozempic. Ozempic at the highest dosage for diabetic patients caused them to lose 6% of their weight.
Lilly plans to submit an application for orforglipron regulatory approval by the end the year.
Lilly reported that a mid-stage study of its next generation obesity drug candidate (a weekly injection retatrutide) led to a weight loss of as much as 24.2% in 48 weeks.
Lilly signed an agreement with China's Laekna biotech last year for the development of a drug to treat obesity that helps patients to lose weight and maintain muscle.
PFIZER
Pfizer stopped developing the experimental weight loss pill danuglipron in October after a patient who was undergoing a clinical trial experienced a potential drug-induced injury to the liver that resolved when the medication was discontinued.
In March, Roche acquired the rights to Zealand Pharma’s petrelintide obesity treatment in a possible deal worth up to $5,3 billion.
Carmot Therapeutics, a Swiss pharmaceutical company, acquired CT-388, an experimental drug for obesity, as part of a $2.7 billion purchase of Carmot Therapeutics that will take place in 2023. Carmot's injection, which is administered once a week, belongs to the same category as Lilly's Mounjaro or Zepbound.
The company announced last year that the early-stage trials of a second drug candidate purchased from Carmot had yielded positive outcomes.
In a year-long, mid-stage study, Amgen's MariTide drug helped obese patients lose up to 20% of body weight.
Amgen says that MariTide late-stage research will begin before the middle of this year.
Analysts say MariTide has similar weight loss benefits to Wegovy and Zepbound but slightly more side effects.
Merck signed an agreement in December worth up to $ 2 billion to license Hansoh Pharma’s oral experimental drug for treating obesity. Merck is now a late competitor to the race to provide a weight loss pill that can replace weekly injections.
The drug HS-10535 is a GLP-1 agonist similar to Wegovy or Zepbound.
ASTRAZENECA
AstraZeneca’s experimental weight loss pill, licensed from China’s Eccogene a year earlier for up to $ 2 billion, has been found safe and tolerable during an early-stage study in November 2024.
The drugmaker has announced that it is moving the once-daily pill AZD5004 into mid-stage clinical trials.
ALTIMMUNE
Altimmune's experimental weight-loss drug pemvidutide helped reduce weight on average by 15.6% and showed weight loss continued at the end treatment.
Some patients, however, experience mild to moderate nausea and vomiting.
VIKING THERAPEUTICS
Viking Therapeutics reported last year that its experimental drug VK2735 helped patients achieve a 14.7% weight loss mean after 13 weeks in a midstage study. The study enrolled 176 obese adults with at least 1 weight-related comorbidity.
The company reported that in November, nine patients who were given the highest dose of 100 milligrams lost an average of 8.2% body weight within 28 days of an early-stage study.
ZEALAND PHARMA
A Danish biotech company, Zealand Pharma, said that a high-dose of petrelintide (its weight-loss drug-candidate) helped reduce weight on average by 8.6% in an early stage study.
In August 2024, the company announced that it would begin talks with other pharmaceutical firms in the second half this year about potential partnerships for developing and commercializing petrelintide.
Therapeutics of Structure
Structure Therapeutics reported last year that its experimental oral weight loss drug reduced weight by an average of 6.2% at the end 12 weeks in a study conducted during mid-stage.
(source: Reuters)